Lead Sponsor

Hoffmann-La Roche

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

No

•Diagnosis of multiple sclerosis, in accordance with the revised McDonald criteria (2010)
•At least 2 documented clinical attacks within the last 2 years prior to screening or one clinical attack in the years prior to screening (but not within 30 days prior to screening)
•Neurologic stability for greater than or equal to (\>/=) 30 days prior to both screening and baseline
•Expanded Disability Status Scale (EDSS) score 0 to 5.5 inclusive

•Primary progressive multiple sclerosis
•Disease duration of more than 10 years in patients with EDSS score less than or equal to (\</=) 2.0 at screening
•Contraindications for MRI
•Known presence of other neurological disorders which may mimic multiple sclerosis
•Pregnancy or lactation
•Requirement for chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
•History of or currently active primary or secondary immunodeficiency
•History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
•Active infection, or history of or known presence of recurrent or chronic infection (for example, hepatitis B or C, Human Immunodeficiency Virus \[HIV\], syphilis, tuberculosis)
•History of progressive multifocal leukoencephalopathy
•Contraindications to or intolerance of oral or IV corticosteroids
•Contraindications to Rebif or incompatibility with Rebif use

Related studies

NCT06433752 · Relapsing Multiple Sclerosis, Multiple Sclerosis

NCT06846281 · Relapsing Multiple Sclerosis

NCT06847724 · Relapsing Multiple Sclerosis

NCT05344469 · Relapsing Multiple Sclerosis

NCT07426991 · Multiple Sclerosis, Remitting-Relapsing Multiple Sclerosis, and more

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis